Online First Nr222

Psychiatr. Pol. ONLINE FIRST Nr 222: 1–14
 
Published ahead of print 22 March 2021
 
 
Marcin Siwek, Adrian Andrzej Chrobak, Zbigniew Sołtys,
Dominika Dudek, Anna Julia Krupa, Janusz Kazimierz Rybakowski

FREE POLISH FULLTEXT: 

FREE ENGLISH FULLTEXT:
 
Summary
Aim. The efficacy of vortioxetine in major depressive disorder has been evaluated in many studies. However, there is a lack of studies assessing vortioxetine in bipolar depression.
Material and method. In 60 patients with bipolar depression, vortioxetine 10–20 mg daily was added to current mood stabilizing medication during 24-week, naturalistic, openlabel study. The most frequent mood stabilizers were lamotrigine, quetiapine, olanzapine, and valproates. The therapeutic efficacy was evaluated by the Clinical Global Impression – Improvement (CGI-I) and Clinical Global Impression – Severity (CGI-S) scales. Patients were classified as responding to vortioxetine when they achieved 1 or 2 points on the CGI-I scale at any stage of observation. The criterion of remission was defined as score 1 at the CGI-S.
Results. 73% of all patients (44/60) responded to vortioxetine and 52% (31/60) achieved clinical remission of depressive symptoms (in mean 8.97 ± 4.05 weeks). There were no significant associations between vortioxetine response/remission rates and: (1) the dose, (2) BD type, (3) clinical stage, (4) presence of rapid cycling, (5) history of psychotic symptoms, analyzed depressive symptoms, and (6) concomitantly used mood stabilizer. 4 patients (6.7%) stopped treatment due to adverse effects (nausea), and 7 patients (11.7%) discontinued treatment due to the phase switch. 14 patients (23%) experienced a loss of vortioxetine effectiveness after the initial response or remission.
Conclusions. The results indicate relatively high rates of response and remission during 24-week treatment in depressed bipolar patients receiving vortioxetine concomitantly with a mood stabilizer. This may indicate that vortioxetine added to a mood stabilizer may constitute an efficient and well tolerated therapeutic option in bipolar depression.
 

ISSN 0033-2674 (PRINT)

ISSN 2391-5854 (ONLINE)


Psychiatria Polska
is an Open Access journal:
Creative Commons: CC-BY
SHERPA RoMEO:
Blue


Zadanie finansowane
w ramach umowy
nr 739/P-DUN/2018
ze środków MNiSW
przeznaczonych
na działalność
upowszechniającą naukę


KRW PTP dziękuje 
firmie PPL – Koral – J.Koral sp.j.
za wsparcie finansowe 
udzielone w 2020 roku




Inne strony PTP:
Other PTP websites:

www.psychiatria.org.pl
www.psychiatriapsychoterapia.pl

www.archivespp.pl
www.psychoterapiaptp.pl

Psychiatria Polska
INDEXED IN:
Thomson Reuters Master List
Science Citation Index Expanded
Journal Citation Reports
(Impact Factor 1,190)

Medline/Index Medicus
PubMed/LinkOut
MNiSW (40 pkt)
Scopus/SCImago
(SJR 0,381; SNIP 0,587)
EMBASE/Excerpta Medica
PsycINFO, EBSCO,
Index Copernicus
Erih Plus, Cochrane Library
CrossRef/DOI

We recommend:

Pharmacological Reports

 


KONTAKT Z REDAKCJĄ - wyłącznie e-mail: redakcja@psychiatriapolska.pl 

Biuro KRW PTP - prenumeraty, faktury:  518-330-994 lub biuro@krwptp.pl 
krwptp.pl